DaVita Inc. announced its fourth quarter 2025 financial results, with consolidated revenues reaching $3.620 billion, an increase from the previous year. However, net income attributable to DaVita Inc. decreased to $234.217 million, down from $259.329 million in Q4 2024, and diluted EPS also saw a decline. The company highlighted strong platform delivery, high-quality care, and ongoing investments.

DaVita exceeded earnings expectations in Q2 2025, driven by strong operating performance in U.S. dialysis and growth in international operations, while managing the financial impact of a cybersecurity event.

DaVita generated $3.224 billion in revenue and $162.9 million in net income in Q1 2025. The company maintained strong operating margins and EPS, while managing rising patient care costs and share repurchases.

DaVita Inc. delivered strong Q4 2024 results, with revenue reaching $3.295 billion, a 4.73% increase YoY. Operating margin expanded to 17.2%, reflecting cost efficiencies and higher reimbursement rates. Adjusted EPS was $2.24, while net income rose significantly to $259.33 million.

DaVita Inc. reported consolidated revenues of $3.264 billion and an operating income of $535 million for the third quarter of 2024. Diluted earnings per share was $2.50, and adjusted diluted earnings per share was $2.59. The company repurchased 2.7 million shares of its common stock at an average price of $147.20 per share.

DaVita Inc. announced financial results for Q2 2024, with consolidated revenues of $3.187 billion and operating income of $506 million. Diluted earnings per share were $2.50, and adjusted diluted earnings per share were $2.59. The company repurchased 2.7 million shares of its common stock at an average price of $140.14 per share.

DaVita Inc. reported consolidated revenues of $3.071 billion for the first quarter of 2024. The company's operating income was $484 million, with a diluted earnings per share of $2.65. They also repurchased 2.1 million shares of common stock.

DaVita Inc. reported consolidated revenues of $3.146 billion for Q4 2023. Operating income was $390 million, with adjusted operating income at $415 million. Diluted earnings per share from continuing operations was $1.62, and adjusted diluted earnings per share was $1.87. The company repurchased 2,903,832 shares of its common stock at an average price of $97.82 per share during the quarter.

DaVita Inc. announced strong financial results for the third quarter of 2023, with consolidated revenues of $3.1 billion, operating income of $496 million, and diluted earnings per share of $2.62. The company has balanced operating discipline with investments in future growth, while focusing on teammate experience and patient care.

DaVita Inc. announced its Q2 2023 financial results, with consolidated revenues of $3.0 billion. The company reported an operating income of $405 million and a diluted EPS of $1.91. Operating cash flow stood at $450 million, while free cash flow reached $260 million.

DaVita Inc. reported consolidated revenues of $2.873 billion, operating income of $312 million, and diluted earnings per share of $1.25 for the quarter ended March 31, 2023. The company's results benefited from an improving macro environment.

DaVita Inc. reported consolidated revenues of $2.917 billion for the three months ended December 31, 2022. The diluted earnings per share from continuing operations was $0.59, and the adjusted diluted earnings per share from continuing operations was $1.11 for the same period. Operating income was $256 million, with an adjusted operating income of $317 million.

DaVita Inc. reported consolidated revenues of $2.949 billion, operating income of $312 million, and diluted earnings per share of $1.13 for the quarter ended September 30, 2022. The company repurchased 2.1 million shares of its common stock at an average cost of $87.10 per share. The third quarter was challenging due to COVID and labor pressures.

DaVita Inc. reported consolidated revenues of $2.927 billion, operating income of $433 million, and diluted earnings per share of $2.30 for the quarter ended June 30, 2022. They repurchased 3.9 million shares of their common stock at an average cost of $95.56 per share. Operating cash flow and free cash flow were $188 million and $95 million, respectively.

DaVita Inc. reported consolidated revenues of $2.818 billion and operating income of $338 million for the quarter ended March 31, 2022. Diluted earnings per share was $1.61. The company repurchased 2.1 million shares of its common stock at an average cost of $110.90 per share.

DaVita Inc. reported consolidated revenues of $2.944 billion and operating income of $389 million for the fourth quarter of 2021. Diluted earnings per share was $1.79, and adjusted diluted earnings per share was $2.02.

DaVita Inc. reported a strong third quarter with consolidated revenues of $2.938 billion and diluted earnings per share of $2.36. The company continues to provide high-quality care amidst a challenging operating environment, including rising COVID-19 cases and a difficult labor market.

DaVita Inc. reported a strong quarter with diluted earnings per share from continuing operations increasing by 63.0% year-over-year. The company saw progress in combating COVID-19 and accelerated investments in integrated kidney care capabilities, growing the number of patients under value-based care arrangements to approximately 10% of the U.S. dialysis patient census.

DaVita Inc. reported Q1 2021 results with a diluted EPS of $2.09, a 15.5% increase from the prior year. Consolidated revenues reached $2.820 billion, and operating income was $443 million. The company faced COVID-19 related challenges, impacting operating income by an estimated $(35) million.

DaVita Inc. reported consolidated revenues of $2.905 billion for Q4 2020. Diluted earnings per share from continuing operations was $1.67, impacted by COVID-19 challenges. The company repurchased 4,193,401 shares for $417 million during the quarter.

DaVita Inc. reported consolidated revenues of $2.924 billion and an operating income of $438 million for the third quarter ended September 30, 2020. Diluted earnings per share from continuing operations were $1.28, and adjusted diluted earnings per share were $1.80. The company also generated $483 million in operating cash flow and $287 million in free cash flow.

DaVita's Q2 2020 results showed a focus on patient and staff safety amidst the COVID-19 pandemic. The company reported consolidated revenues of $2.880 billion, operating income of $410 million, and diluted earnings per share from continuing operations of $1.62.

DaVita Inc. reported consolidated revenues of $2.841 billion, operating income of $465 million, and diluted earnings per share of $1.81 for the first quarter of 2020. The company also repurchased 4,052,298 shares of its common stock at an average cost of $74.81 per share.

DaVita Inc. reported consolidated revenues of $2.899 billion, operating income of $463 million, and diluted earnings per share from continuing operations of $1.86 for the fourth quarter of 2019. The company repurchased 8,368,506 shares of its common stock at an average cost of $64.80 per share.